Large target and heart volumes predicted replanning during proton therapy for thoracic cancer
In 180 thoracic proton therapy patients, larger clinical target volume and heart volume independently predicted the need for adaptive replanning.
In 180 thoracic proton therapy patients, larger clinical target volume and heart volume independently predicted the need for adaptive replanning.
Simulated proton minibeams preserved spatial fractionation and target homogeneity for targets up to 20 centimetres with depth-adapted beam widths and spacing.
After 66% of couch-angle changes, motion exceeded tolerance, and 0.5-millimetre and 0.5-degree errors reduced near-minimum target dose by 7.6%.
Across 500 clinical cases, automated planning preserved target coverage and was associated with lower doses to multiple critical structures than earlier manual planning.
Mean breast target displacement was below 1.3 mm in every direction, with calculated respiratory margins of approximately 1 mm.
Gastrointestinal motility reduced single-fraction target coverage and broadened organ-at-risk dose ranges, while conventional fractionation substantially attenuated the interplay effect.
The patient-specific framework outperformed three comparison methods and reconstructed respiratory anatomy in 15.6 milliseconds per frame.
Live magnetic resonance imaging–ultrasound fusion achieved under 4 mm registration accuracy and under 5 mm needle localization in two clinical implants.
Weekly monitoring identified week 2 triggers for nodal targets and contralateral parotids, with later week 4 triggers for primary targets.
K-means matched hybrid optimization for margin volume while reducing median computation time from 306.9 seconds to 0.19 seconds.
98.98% of virtual contrast-enhanced MRI scans were rated suitable for diagnosis, and 92.33% for tumor delineation.
A physics-constrained network reconstructed pelvic cone-beam computed tomography from two simulated radiographs with substantially lower error than generative baselines.
Respiratory gating more than halved cranio-caudal motion, while motion-related target-dose deviations largely diminished after accumulation across more than three fractions.
No single patient-specific quality assurance method covered all stereotactic radiotherapy risks, supporting combinations of measurement, independent calculation, imaging, and monitoring.
Mean treated-breast displacement was 1.6 mm, with larger patient-specific changes near treatment completion and during follow-up.